SciClone Pharmaceuticals Inc. bought NovaMed Pharmaceuticals Inc., a Chinese specialty pharmaceutical company backed by American venture capital firm Atlas Ventures, in a cash and stock deal worth up to nearly $105 million.
SciClone (NASDAQ: SCLN), basedin Foster City, said the combined revenue of the company in 2011 would be $140 million to $145 million.
SciClone CEO Freidhelm Blobel told the San Francisco Business Times last year that his company would seek out deals in China, where it already sells its hepatitis B and hepatitis C treatment, Zadaxin.
This is very useful, although it will be important to help simply click that web page link: usa sarms
ReplyDelete